Skip to main content

Ciphergen, Beckman Coulter Alliance Hopes to Automate Proteomics Research

NEW YORK, March 5 - Ciphergen Biosystems and Beckman Coulter on Tuesday said they plan to automate clinical proteomics research.

Terms of the agreement call for Ciphergen to combine its SELDI protein chip biomarker system with a custom version of Beckman's Biomek 2000 system. The resulting "turnkey" platform will be marketed to industry, academia, and government institutes, the companies said. 

Financial terms of the agreement were not disclosed.

"We are happy that we can now make these solutions available broadly through this alliance with Beckman Coulter," William E. Rich, president and CEO of Ciphergen, said in a statement. The firms said their alliance hopes to speed sample throughput five-fold and improve reproducibility.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.